采用开环并构建五元环状分子内氢键的策略,设计、合成了5个4-取代苯氧基喹啉类化合物,并通过氢谱、碳谱和质谱对其进行了结构确证。体外活性测试结果显示,3-乙酰氨基-4-(3-(三氟甲基)苯氧基)-6-(2-氨基吡啶-5-)喹啉(9a)具有一定的哺乳...采用开环并构建五元环状分子内氢键的策略,设计、合成了5个4-取代苯氧基喹啉类化合物,并通过氢谱、碳谱和质谱对其进行了结构确证。体外活性测试结果显示,3-乙酰氨基-4-(3-(三氟甲基)苯氧基)-6-(2-氨基吡啶-5-)喹啉(9a)具有一定的哺乳动物雷帕霉素靶蛋白(the mammalian target of rapamycin,mTOR)抑制活性(IC50=5.78μmol/L);3-氨基-4-(3-(三氟甲基)苯氧基)-6-(2-氨基吡啶-5-)喹啉(5c)对肺癌细胞株A549细胞具有中等强度的抗增殖活性(IC50=36.2μmol/L)。展开更多
A series of 4-phenoxy quinoline-based mevalonolactone derivatives have been synthesized and evaluated as 3-hydroxy-3-methylglutaryl CoA reductase （HMG CoA reductase） inhibitors.One member of this series,（4R,6S）-6-...A series of 4-phenoxy quinoline-based mevalonolactone derivatives have been synthesized and evaluated as 3-hydroxy-3-methylglutaryl CoA reductase （HMG CoA reductase） inhibitors.One member of this series,（4R,6S）-6-{（E）-2-[6-fluoro-7-chloro-4-（4-fluorophenoxy-quinoline）-3-yl-]-ethenyl}-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one （3d）,showed more potent activity than rosuvastatin or pitavastatin to inhibit the rat HMG CoA reductase in vitro.This compound was selected for the extensive preclinical development as a potential hypocholesterolemic candidate.展开更多
文摘采用开环并构建五元环状分子内氢键的策略,设计、合成了5个4-取代苯氧基喹啉类化合物,并通过氢谱、碳谱和质谱对其进行了结构确证。体外活性测试结果显示,3-乙酰氨基-4-(3-(三氟甲基)苯氧基)-6-(2-氨基吡啶-5-)喹啉(9a)具有一定的哺乳动物雷帕霉素靶蛋白(the mammalian target of rapamycin,mTOR)抑制活性(IC50=5.78μmol/L);3-氨基-4-(3-(三氟甲基)苯氧基)-6-(2-氨基吡啶-5-)喹啉(5c)对肺癌细胞株A549细胞具有中等强度的抗增殖活性(IC50=36.2μmol/L)。
基金The State New Drug Innovation (Grant No. 2009ZX09301-007)Shanghai Rising-Star Program (Grant No. 08QB1403800)Shanghai Innovation Action Project (Grant No. 09431901300)
文摘A series of 4-phenoxy quinoline-based mevalonolactone derivatives have been synthesized and evaluated as 3-hydroxy-3-methylglutaryl CoA reductase （HMG CoA reductase） inhibitors.One member of this series,（4R,6S）-6-{（E）-2-[6-fluoro-7-chloro-4-（4-fluorophenoxy-quinoline）-3-yl-]-ethenyl}-3,4,5,6-tetrahydro-4-hydroxy-2H-pyran-2-one （3d）,showed more potent activity than rosuvastatin or pitavastatin to inhibit the rat HMG CoA reductase in vitro.This compound was selected for the extensive preclinical development as a potential hypocholesterolemic candidate.
